Shares of AbCellera Biologics Inc. (NASDAQ:ABCL – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year price […]

Related Keywords

Eli Lilly , Abcellera Biologics , Abcellera Biologics Inc , Arrowmark Colorado Holdings , Renaissance Technologies , Nasdaq , Keycorp , Lazard Asset Management , Get Free Report , Cellera Biologics , Mark Colorado Holdings , Street Corp , Asset Management , Prosight Management , Get Free , Cellera Biologics Inc , Confo Therapeutics , Abcellera Biologics Daily , Nasdaq Abcl , Abcl , Medical , Ratings , Consensus ,